SCHEMBL3364012

SCHEMBL3364012

CC(C)Oc1ccc(NC(=O)N2CCN(c3ncnc4cc(OCCCN5CCOCC5)ccc34)CC2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 19/20 0.81
FLT3 P36888 5/20 0.81
KIT P10721 4/20 0.81
CSF1R P07333 3/20 0.81
PLK4 O00444 1/20 0.69
GAK O14976 1/20 0.69
EPHB6 O15197 1/20 0.69
STK10 O94804 1/20 0.69
EGFR P00533 1/20 0.69
NTRK1 P04629 1/20 0.69
LCK P06239 1/20 0.69
FGFR1 P11362 1/20 0.69
SRC P12931 1/20 0.69
PDGFRA P16234 1/20 0.69
FLT1 P17948 1/20 0.69
FGFR2 P21802 1/20 0.69
FGFR4 P22455 1/20 0.69
FGFR3 P22607 1/20 0.69
AXL P30530 1/20 0.69
FLT4 P35916 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365789 0.96 PDGFRB (0.81) PDGFRBFLT3KITCSF1RPLK4
SCHEMBL3364014 0.91 PDGFRB (0.67) PDGFRBFLT3KITCSF1RPLK4
SCHEMBL29460355 0.90 PDGFRB (1.00) PDGFRBFLT3KITCSF1RPLK4
SCHEMBL317630 0.90 PDGFRB (1.00) PDGFRBFLT3KITCSF1RPLK4
SCHEMBL13114412 0.89 PDGFRB (0.79) PDGFRBFLT3KITCSF1RPLK4
SCHEMBL5907718 0.88 PDGFRB (0.77) PDGFRBFLT3KITCSF1RPDGFRA
SCHEMBL3398407 0.87 PDGFRB (0.67) PDGFRBFLT3KITCSF1R
SCHEMBL12048925 0.86 PDGFRB (0.64) PDGFRBFLT3KITCSF1RPLK4
SCHEMBL3364542 0.86 PDGFRB (0.84) PDGFRBFLT3KITCSF1R
SCHEMBL5907734 0.84 PDGFRB (0.77) PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309569-B1 N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors MILLENNIUM PHARM INC (US) 2010-10-06 EP claimed
US-6956039-B2 Nitrogenous heterocylic compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-18 US claimed
US-20040186110-A1 Nitrogenous heterocylic compounds MILLENNIUM PHARMACEUTICALS, INC. 2004-09-23 US claimed
EP-1309569-B1 N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors MILLENNIUM PHARM INC (US) 2010-10-06 EP disclosed
US-20060063770-A1 Nitrogenous heterocyclic compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-03-23 US disclosed
US-6956039-B2 Nitrogenous heterocylic compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-18 US disclosed
US-20040186110-A1 Nitrogenous heterocylic compounds MILLENNIUM PHARMACEUTICALS, INC. 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063770-A1 Nitrogenous heterocyclic compounds WNK2, CDK5, WNK1 PDGFRB 6/4885FLT3 369/4885KIT 597/4885
US-20040186110-A1 Nitrogenous heterocylic compounds WNK2, CDK5, WNK1 PDGFRB 7/4885FLT3 281/4885KIT 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.